Replies to post #669922 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

You are right, the comparison isn’t fair. SeaGen’s tech is merely a chemo attached to an antibody seeking one, just one antigen to kill the targeted cell. It is safer than just giving someone chemo though, because it limits damage to healthy cells. Its weakness is that it easily allows tumor escape.

NWBO’s technology is massively broad spectrum and targeted to the patient’s tumor cell antigens. It targets a multitude of different antigens on a multitude of different types of tumor cells. Thus limiting tumor escape. It doesn’t carry a manmade chemo payload, because it uses DCVax-l directed t-cells to attack and kill the target.

I was previously asked to compare the two company’s technologies. I did.

The post you commented on was a follow up making some further timing observations.

BTW, prerevenue companies are bought out all the time. Some for very large amounts. The purchasing BP uses future revenue calculations to justify their acquisition price.

[meirluc]

Not a good comparison Hankmanhub. Within the next 3-5 years, Seagen's
technological accomplishments will amount to a fraction of the life saving
technology that will be introduced by NWBO and that difference will also be
reflected in both companies' MC or the MC of the entities who purchase those
two companies.

Unless some other extremely efficacious cancer treatment can be rapidly
developed and introduced into the market, DCVax is going to be the next
major treatment for most solid cancers because to date, both DCVax-L and
D have shown in their respective trials, a substantial efficacy and smaller
combo trials utilizing DCVax-L with adjuvants (poly-ICLC, keytruda) are showing
an ever increasing life extending capacity.

There is therefore overwhelming evidence from several trials and RWE
(compassionate patients) that DCVax works and will likely improve.

The only major questions remaining are:
1. Right after MHRA approval, how long will NWBO carry the burden alone or will there be soon
thereafter a partnership or BO?
2. The relative difficulty involved ( time and expenses) to bring the treatments to patients with GBM
and later to patients with other solid cancers while NWBO is working alone, with partnership or a BO?
3. When can the Edens automatic manufacturing system be validated and how will that system affect
questions 1 and 2?

[skitahoe]

Hank,

You're right about SGEN not being comparable to NWBO today, but if we're right about the DCVax's working in many solid cancers, the $2 billion SGEN is earning will be a tiny percentage of what the DCVax's are earning. We just need to be patient enough to let NWBO demonstrate what it really has. IMGN should have been worth at least half of what SGEN was, and in time probably more, but they sold out for about 1/4 of it. Be wary of selling out too soon, IMGN certainly did IMHO.

Gary